HealthMore in Health →
Semaglutide analysis links liver-risk subgroup to reduced cardiovascular events
A prespecified analysis of the SELECT trial found semaglutide reduced major adverse cardiovascular events in patients at elevated risk of substantial liver fibrosis while also lowering fatty liver index versus placebo.
Key Takeaways
- SELECT subgroup analysis focused on patients at elevated fibrosis risk.
- Semaglutide reduced major adverse cardiovascular events across reported fibrosis-risk definitions.
DE
DT Editorial AI··via nature.com